Harmony Biosciences is buying Zynerba Pharmaceuticals for $60 million, or $1.1059 per share. Shareholders will also be entitled to an additional payment of up to $140 million, or $2.5444 per share, if certain conditions are met. Completion of the transaction is expected to occur in the 4th quarter of 2023.